AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02478593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational booklet
Description: Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
Study NCT02355795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-fat diet
Description: Energy from total fat, protein and carbohydrates are 20%, 14% and 66%, respectively
Study NCT02355795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-fat diet
Description: Energy from total fat, protein and carbohydrates are 30%, 14% and 56%, respectively
Study NCT02355795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-fat diet
Description: Energy from total fat, protein and carbohydrates are 40%, 14% and 46%, respectively
Study NCT01252238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
Study NCT01252238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan and Aliskiren
Description: Subject taking combination of valsartan and aliskiren.
Study NCT01252238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: Taking Amlodipine as prescribed by MD for management of high blood pressure.
Study NCT01920373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A (corticosteroid injection group)
Study NCT01920373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B (platelet rich plasma injection group)
Study NCT00285415 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel and Carboplatin
Description: docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
Study NCT02708628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scar excision
Description: Scar excision in second c-section
Study NCT01597687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: 1 blood sample will be collected from each subject.
Study NCT01597687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Quality of Life and HE questionnaires.
Study NCT01107574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
Study NCT01107574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Description: Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
Study NCT01107574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gabapentin and Osteopathic Manipulative Medicine
Description: Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
Study NCT01343368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
Study NCT01343368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoietic cell transplant
Description: Conventional bone marrow transplant regimen.
Study NCT01343368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: reduced intensity allogeneic HCT
Description: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
Study NCT03391648 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation only
Study NCT01329601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StaCog, stage specific cognitive Intervention
Description: StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
Study NCT01329601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: booklet based training
Description: Home based training of episodic memory using paper-pencil exercizes
Study NCT01906294 — intervention group
Intervention type: DRUG
Intervention: antidiabetic treatment (ATC A10B)
Study NCT02014857 — intervention group
Intervention type: PROCEDURE
Intervention: Gingival Crevicular Fluid Sampling
Study NCT03811067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: Transversus abdominis plane block will be performed bilaterally after the surgery.
Study NCT01092702 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
Study NCT03811067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath block
Description: Rectus sheath block will be performed bilaterally after the surgery.
Study NCT04256733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer
Description: Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
Study NCT04256733 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer
Description: Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
Study NCT01666002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Treatment (Pulsed Nd:YAG 1064 nm Laser)
Description: 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
Study NCT02794402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Bydureon (Exenatide once weekly) injections s.c.
Study NCT02794402 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once weekly injections sc
Study NCT04289857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic training
Description: Starting from a sitting position on a stretcher, with dorsolumbar flexion, it is required to maintain that posture throughout the exercise. Sliding with the straight leg sitting consists of performing alternate movements. First, knee extension and dorsal ankle flexion will be performed, increasing neural tension, combined with cervical extension (to decrease neural tension) in the first instance. Subsequently, knee flexion and plantar ankle flexion (decreasing neural tension) combined with cervical flexion (increasing neural tension) will be performed. The dosage of the technique will be: two seconds for each movement, with 10 repetitions of each one. All sessions will be led by one of the group's researchers.
Study NCT01178151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10mg daily orally
Study NCT04148248 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT00673049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 751,871 (Figitumumab)
Description: CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
Study NCT00673049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib (one tablet of 150 mg/day PO).
Study NCT00673049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
Study NCT04269928 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular chemical ablation of adrenal gland
Description: Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
Study NCT06360835 — intervention group
Intervention type: PROCEDURE
Intervention: total hip arthroplasty
Study NCT02511431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
Study NCT02511431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
Study NCT00848913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation with strength training
Description: Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
Study NCT00848913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation without strength training
Description: Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
Study NCT02922751 — intervention group
Intervention type: OTHER
Intervention: Liver Stiffness Measurement (LSM)
Description: LSM will be measured via transient elastography utilizing the non-invasive FibroScan™ ultrasound device. LSM will be measured at Baseline, Year 1 and Year 2 visits.
Study NCT06095921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Management Intervention Program
Description: SSc, the course of the disease, symptoms and coping strategies, medications and treatment methods? The importance of exercise for individuals with SSc, and how to create an action plan for an exercise? were discussed. What are fatigue and its symptoms? How can we protect our articular-energy and how should a quality rest be? What is pain and what are coping approaches? What is the pain-related area of influence? What are body image problems, how to use problem solving approach and what is its importance? What is Stress? What is mindfulness? What are mindfulness exercises? What are the ways to cope with stress? What are the daily life occupations and how can we facilitate them? How can we solve problems in difficult occupations? How to create an occupation plan to facilitate daily occupations? What are oral stretching exercises and how to do them? What are the factors affecting sleep? What is advocacy and why is it important? Answers to these questions were sought.
Study NCT00249301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8054
Description: MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
Study NCT04356547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic intubation with laryngeal mask AuraGain
Description: Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator.
Study NCT04356547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic intubation without laryngeal mask
Description: Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator.
Study NCT00780884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: 16 sessions of acupuncture treatment, twice a week.
Study NCT02421705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sample collection
Description: Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
Study NCT03484962 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
Study NCT03484962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT03484962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT03020992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * pharmaceutical form: solution for infusion in prefilled syringe~* concentration: 200 mg/mL~* route of administration: subcutaneous
Study NCT01543438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Prescription (additional education)
Description: receives video prescriptions
Study NCT02511431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00874575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00874575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT00874575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-hydroxy-Beta-methylbutyrate
Study NCT00874575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-hydroxy-Beta-methylbutyrate and Vitamin D
Study NCT04179838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep-Deprived
Description: Sleep for 4 hours at home.
Study NCT04179838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Sleep Deprived
Description: Sleep for 8 hours at home.
Study NCT01453920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Ranibizumab 0.05cc (10mg/ml)
Study NCT01453920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal Ranibizumab 0.05cc (10mg/ml)
Study NCT03545529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Innovativ supported
Description: addition of connected tools and stronger accompaniment to prevent falls
Study NCT01977352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
Study NCT01431716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFI/ACT-385781A
Study NCT01977352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: 20 cc of bupivacaine 0.25%
Study NCT02755545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Product A
Description: Product A applied topically to the entire face or other affected area of the skin once daily
Study NCT02755545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Product B
Description: Product B applied topically to affected area of the skin 1 to 3 times daily
Study NCT02467088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Homeopathic Remedy
Description: Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
Study NCT00706459 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
Study NCT03066154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral docetaxel (ModraDoc/r)
Description: Weekly once- or twice daily ModraDoc/r
Study NCT03066154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: ADT according to the standard of care
Study NCT03066154 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high-dose intensity-modulated radiation therapy
Description: 77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
Study NCT04089280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sanprobi Barrier-multispecies probiotic
Description: Multi-strain probiotic Sanprobi Barrier (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus lactis W19, Lactobacillus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24) or placebo. Patients will be randomized to one of the two products (A or B) each containing probiotic/placebo and administered for 12 weeks. After 12 weeks of supplementation, the probiotic/placebo product A or B will be discontinued and reintroduced again after next 4 weeks - patients will be switched to the other A or B group of probiotic/placebo arm. Patients will be administered with 4 capsules per day for 24 weeks (12 weeks for group A probiotic/placebo and 12 weeks for group B probiotic/placebo allowing 4 weeks washout between the group assignment).
Study NCT04089280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Carrier material of Sanprobi Barrier-multispecies probiotic product, not containing bacterial strains,similar appearance as the probiotic
Study NCT04056507 — intervention group
Intervention type: PROCEDURE
Intervention: Immunolabeling
Description: Immunolabeling of abnormalities observed by the cell study in flow cytometry.
Study NCT01575119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
Study NCT01575119 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
Study NCT01575119 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
Study NCT03630588 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Surimi intervention
Description: The bioactive compounds used to obtain the surimi product are:~* Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.~* EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States.~* Probiotic BPL1~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi.
Study NCT03630588 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Conventional surimi~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi.
Study NCT03032588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: Participants will receive single dose (0.5 milliliter \[mL\]) of sIPV as a suspension for intramuscular injection on Day 1.
Study NCT03032588 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cIPV
Description: Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 300 mg
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 10 to 35 mg/kg
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 10 to 35 mg/kg